Exosome Claims: What You Can Say, and What Gets Brands Fined

Exosome claims are where brands die quietly. The record is blunt. China's March 15 consumer-rights broadcast gutted the domestic consumer-exosome market in 2026 over clinical-claim abuse. The FDA has sent warning letters to exosome companies since late 2024. A single FTC action over an 'organic' claim cost $1.76 million. The pattern is constant across markets: the product rarely fails — the copy does.

The ladder: same product, three tiers of wording

Regulators in every market read claims on one axis — what does the copy promise?

• Safe (cosmetic, appearance level). "Hydrates and helps skin look smoother." "Helps maintain the skin barrier." "Appears soothed." This is the EU's common-criteria territory (Regulation (EU) No 655/2013: lawful, truthful, supporting evidence, honest, fair, informed decision-making) and the US advertising standard. Our programs ship on-pack copy at exactly this level — appearance claims only.
• Risky (implication level). "Stimulates collagen synthesis." "Regenerates skin cells." "Promotes cellular repair." These phrases appear in FDA warning letters to exosome companies: structure/function implications that turn a cosmetic into an unapproved drug in the reviewer's eyes.
• Over the line (drug-claim level). "Treats eczema." "Repairs wounds." China's market regulators cited their own examples in 2026: "cell-level repair," "a water-gloss injection without breaking skin," "painless thermage" were all cited as medical-effect misrepresentation — alongside notices that human-derived exosome material is not a permitted cosmetic ingredient there at all.

The same vial sits on all three rungs. Nothing about the liquid changes between them — only the sentence around it.

The three habits that keep a brand safe

First: write the claims boundary before the artwork. One product, one sentence of allowed claim space, decided against the destination market's framework (EU CPNP file, US MoCRA listing, China notification) — then copywriters work inside it, not around it. A claim removed at the copy stage is cheap; a claim defended without data is expensive.

Second: keep the documentation chain that backs even the safe claims. "Helps maintain hydration" still needs a file behind it — batch COAs, characterization baselines, the published evidence base (a 2026 systematic review of 19 human studies reports short-term hydration and appearance signals, honestly caveated). When a claim is challenged, the answer is a document, not a defense.

Third: never borrow the incumbent's copy. Half the risky phrases circulating in this category were lifted from another supplier's website — often the very company the regulator cited. Regulators do not accept "the industry says this" as a defense; neither does a clinic's legal review.

The sourcing corollary

If you source exosome products rather than make them, the ladder is your vetting tool: ask a supplier for their on-pack wording and hold it against the middle rung. A supplier whose default copy says "repairs" or "treats" is exporting their claim risk to your shelf.

Our programs are written at the safe rung by default — see the claims discipline section in any playbook, or bring your copy for a route check.